Table 1.
Ab name | Source | Neutralizing activity | Neutralizing mechanism | Protective efficacy | Refsb |
---|---|---|---|---|---|
S230.15 m396 mAbs |
Human | Neutralize human (strains GD03, Urbani, Tor2) and palm civet (strains SZ3, SZ16) SARS-CoV infection | Recognize epitopes (residues 408, 442, 443, 460, 475) on SARS-CoV S1 protein, interfering with RBD–ACE2 receptor interaction | Protect mice against challenge of SARS-CoV (strains Urbani, rGD03, or rSZ16) | [9] |
S109.8 S227.14 S230.15 mAbs |
Human | Neutralize human (Urbani, GZ02, CUHK-W1), palm civet (HC/SZ/61/03), and raccoon dog (A031G) SARS-CoV infectious clones containing S variants | Inhibit the binding of SARS-CoV RBD–ACE2 receptor | Protect mice against challenge of SARS-CoV infectious clones (Urbani, GZ02, HC/SZ/61/03) or mouse-adapted strain (MA15) | [10] |
80R scFv, mAb |
Human | Neutralize live SARS-CoV (strain Urbani) infection | Recognize epitopes on SARS-CoV S1 (residues 261–672), blocking RBD–ACE2 binding and inhibiting syncytium formation | NA | [11] |
CR3022 CR3014 scFv, mAb |
Human | Neutralize live SARS-CoV (strain HKU-39849) infection; CR3022 could neutralize CR3014 escape variants | Recognize epitopes on SARS-CoV RBD (residues 318–510); CR3022 binds SARS-CoV-2 RBD with high affinity | CR3014 protects ferrets against SARS-CoV (strain HKU-39849) infection | [13] |
33G4 35B5 30F9 mAbs |
Mouse | Neutralize human (strains GD03, Tor2) and palm civet (SZ3) pseudotyped SARS-CoV infection | Recognize epitopes on SARS-CoV RBD, blocking RBD–ACE2 receptor binding | NA | [12] |
MERS-27 m336 MERS-GD27 MCA1 mAbs, Fabs |
Human | Neutralize divergent strains of pseudotyped and live (strain EMC2012) MERS-CoV infection | Recognize a number of key epitopes on MERS-CoV RBD protein, blocking RBD–DPP4 receptor binding | Prophylactically and therapeutically prevent and treat MERS-CoV (strain EMC2012) challenge in hDPP4-Tg mice, rabbits, or common marmosets | [3,8] |
4C2 h hMS-1 mAbs |
Humanized | Neutralize divergent strains of pseudotyped and live (strain EMC2012) MERS-CoV infection | Recognize epitopes (residues 510, 511, 553) on MERS-CoV RBD protein, blocking RBD–DPP4 receptor binding | Prevent MERS-CoV (strain EMC2012) challenge in Ad5/hDPP4-transduced or hDPP4-Tg mice | [3] |
Mersmab1 4C2 D12 mAbs |
Mouse | Neutralize pseudotyped and live (strain EMC2012) MERS-CoV infection | Recognize a number of key epitopes on MERS-CoV RBD protein, blocking RBD–DPP4 receptor binding | NA | [3] |
HCAb-83 Nb |
Dromedary camel | Neutralizes live MERS-CoV (strain EMC2012) infection | Recognizes epitope (residue 539) on MERS-CoV RBD protein | Prophylactically prevents MERS-CoV (strain EMC2012) challenge in hDPP4-Tg mice | [8] |
NbMS10-Fc Nb |
Llama | Neutralizes multiple strains of pseudotyped and live (strain EMC2012) MERS-CoV infection | Recognizes epitope (residue 539) on MERS-CoV RBD protein | Prophylactically and therapeutically prevents and treats MERS-CoV (strain EMC2012) challenge in hDPP4-Tg mice | [8] |
Abbreviations: Ab, antibody; Ad5/hDPP4-transduced mice, adenovirus serotype 5-hDPP4-transduced mice; hDPP4-Tg mice, human DPP4-transgenic mice; NA, not applicable; rGD03 or rSZ16, recombinant SARS-CoVs bearing the S protein of GD03 or SZ16; S, spike.
Note: Due to space limitations, some review articles, rather than original research papers reporting the antibodies, are cited.